Recent Press Releases

Vertex Announces a Signed Letter of Intent to Enable Public Reimbursement of KALYDECO(R) (ivacaftor) in Canada for Eligible People with Cystic Fibrosis

Vertex Announces a Signed Letter of Intent to Enable Public Reimbursement of KALYDECO(R) (ivacaftor) in Canada for Eligible People with Cystic Fibrosis -Before patients can get access through public...

Type 2 diabetes: Investigational compound empagliflozin as an add-on therapy significantly reduced blood glucose and body weight in two newly presented phase III trials

-- In a two-year study, empagliflozin as add-on to metformin demonstrated significantly greater decreases in A1C (blood glucose), body weight and blood pressure compared with glimepiride as add-on

Lilly Announces Detailed Results from Two Phase III Studies Testing Both Doses of Dulaglutide vs. Insulin Glargine

AWARD-2: Once-Weekly Dulaglutide 0.75 mg Non-Inferior, 1.5 mg Superior in HbA1c Reduction from Baseline with Sustained Weight Loss and Lower Risk for Hypoglycemia

Amgen Joins The National Cancer Institute And Research Partners To Help Accelerate Development Of Personalized Treatment Approaches For Squamous Cell Lung Cancer

Lung-MAP Trial Will Test Five Investigational Approaches, Including Amgen's Rilotumumab, an Investigational Fully Human Monoclonal Antibody

Allergan Reiterates its Belief that Valeant's Business Model is Unsustainable

Re-Revised Proposal Creates Significant Risks and Uncertainties for Allergan Stockholders Numerous Third Parties Agree IRVINE, Calif., Jun 16, 2014 (BUSINESS WIRE) -- Allergan, Inc. AGN -0.15%...

Sanofi Reports Positive Phase 3 Results for Toujeo(R)

Sanofi Reports Positive Phase 3 Results for Toujeo(R) Jun 14, 2014 (GLOBE NEWSWIRE via COMTEX) -- Sanofi Reports Positive Phase 3 Results for Toujeo® (insulin glargine [rDNA origin] injection,...

Sanofi and Medtronic to Form Strategic Alliance in Diabetes to Improve Patient Experience and Outcomes

Sanofi and Medtronic to Form Strategic Alliance in Diabetes to Improve Patient Experience and Outcomes Initial focus on insulin-device combinations and care management services PARIS and MINNEAPOLIS,...

Sanofi's Lyxumia® (lixisenatide) Showed More Pronounced After-Test-Meal Blood Sugar Lowering Than Liraglutide When Both Were Added to Insulin Glargine

Sanofi's Lyxumia® (lixisenatide) Showed More Pronounced After-Test-Meal Blood Sugar Lowering Than Liraglutide When Both Were Added to Insulin Glargine PARIS, Jun 14, 2014 (Canada NewsWire via...

Cities for Life Increased Community Support and Showed Improved Clinical Measures for People Living With or At Risk for Type 2 Diabetes

Cities for Life Increased Community Support and Showed Improved Clinical Measures for People Living With or At Risk for Type 2 Diabetes During the 1-year program, patients showed statistically...

Patients Continuing On Sanofi's Lantus® Had Lower Blood Sugar Levels Than Those who Switched to Insulin Detemir

Patients Continuing On Sanofi's Lantus® Had Lower Blood Sugar Levels Than Those who Switched to Insulin Detemir Real World Outcome Study of Patients with Type 2 Diabetes Presented at American...

New phase 3 study shows efficacy and safety of Victoza® (liraglutide [rDNA origin] injection) for the treatment of type 2 diabetes in adults with moderate renal impairment

New phase 3 study shows efficacy and safety of Victoza® (liraglutide [rDNA origin] injection) for the treatment of type 2 diabetes in adults with moderate renal impairment San Francisco, U.S., 14...

New one-year data of IDegLira shows glucose-lowering effect was maintained for people with type 2 diabetes

New one-year data of IDegLira shows glucose-lowering effect was maintained for people with type 2 diabetes San Francisco, U.S., 14 June 2014 – New Phase 3a findings show IDegLira, the...

Sanofi and Medtronic to Form Strategic Alliance in Diabetes to Improve Patient Experience and Outcomes

Sanofi and Medtronic to Form Strategic Alliance in Diabetes to Improve Patient Experience and Outcomes Paris and Minneapolis, Minn. - June 14, 2014 - Sanofi (EURONEXT: SAN and NYSE: SNY) and...

GSK presents new data for once-weekly Tanzeum/Eperzan (albiglutide) showing blood glucose lowering up to three years in type 2 diabetes

GSK presents new data for once-weekly Tanzeum/Eperzan (albiglutide) showing blood glucose lowering up to three years in type 2 diabetes New data from secondary analyses of four randomised phase III...

Novartis Holly Springs facility becomes first US pandemic-ready site licensed by the FDA to produce cell-culture influenza vaccines

Novartis Holly Springs facility becomes first US pandemic-ready site licensed by the FDA to produce cell-culture influenza vaccines Cell-culture technology is a modern alternative to manufacture...

Type 2 Diabetes: Investigational Empagliflozin/Linagliptin Combination Tablet Showed Reduction in Blood Glucose in Two Phase III Trials

- For those taking metformin, empagliflozin/linagliptin combination tablet showed statistically significant reductions in blood glucose vs.

Studies Show Investigational New Insulin Glargine Product from Lilly and Boehringer Ingelheim Similar Safety and Efficacy Profile to Lantus®

Companies present comprehensive data for LY2963016, investigational new insulin glargine product

SAN FRANCISCO,

Lilly's Once-Weekly Dulaglutide Shows Similar Reductions in Average Blood Glucose Levels as Once-Daily Liraglutide in Head-to-Head Trial

Once-Weekly Dulaglutide 1.5 mg Also Demonstrates Weight Loss, Low Rates of Hypoglycemia in AWARD-6 Trial

SAN FRANCISCO,

Lilly's Basal Insulin Peglispro Shows Novel Mechanism of Action

Data presented at the 74th American Diabetes Association Scientific Sessions® expand body of evidence for the mechanism of action of basal insulin peglispro in healthy human subjects